Respiratory Medicine
Volume 104, Issue 6 , Pages 780-787 , June 2010

Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections

  • Charlene M. Prazma

      Affiliations

    • Respiratory Medical Development Center, GlaxoSmithKline, Research Triangle Park, Five Moore Drive, NC 27709, USA
    • ,
  • Kenneth M. Kral

      Affiliations

    • Respiratory Medical Development Center, GlaxoSmithKline, Research Triangle Park, Five Moore Drive, NC 27709, USA
    • ,
  • Nadeem Gul

      Affiliations

    • GlaxoSmithKline, Stockley Park, London, UK
    • ,
  • Steve W. Yancey

      Affiliations

    • Respiratory Medical Development Center, GlaxoSmithKline, Research Triangle Park, Five Moore Drive, NC 27709, USA
    • ,
  • David A. Stempel

      Affiliations

    • Respiratory Medical Development Center, GlaxoSmithKline, Research Triangle Park, Five Moore Drive, NC 27709, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 483 5325; fax: +1 919 483 4300.

Received 19 November 2009 ,Accepted 8 February 2010.

References 

  1. Johnston NW, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol. 2005;115:132–138
  2. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ. 1995;310:1225–1229
  3. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307:982–986
  4. Wark PA, Johnston SL, Moric I, Simpson JL, Hensley MJ, Gibson PG. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J. 2002;19:68–75
  5. Chauhan AJ, Inskip HM, Linaker CH, Smith S, Schreiber J, Johnston SL, et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet. 2003;361:1939–1944
  6. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet. 2002;359:831–834
  7. Message SD, Johnston SL. Viruses in asthma. Br Med Bull. 2002;61:29–43
  8. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest. 1997;112:591–596
  9. Gern JE, Busse WW. Association of rhinovirus infections with asthma. Clin Microbiol Rev. 1999;12:9–18
  10. Rakes GP, Arruda E, Ingram JM, Hoover GE, Zambrano JC, Hayden FG, et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med. 1999;159:785–790
  11. Thumerelle C, Deschildre A, Bouquillon C, Santos C, Sardet A, Scalbert M, et al. Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France). Pediatr Pulmonol. 2003;35:75–82
  12. Dales RE, Schweitzer I, Toogood JH, Drouin M, Yang W, Dolovich J, et al. Respiratory infections and the autumn increase in asthma morbidity. Eur Respir J. 1996;9:72–77
  13. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med. 1996;154:654–660
  14. Storr J, Lenney W. School holidays and admissions with asthma. Arch Dis Child. 1989;64:103–107
  15. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054–1063
  16. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985–1997
  17. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008;149:33–42
  18. Khetsuriani N, Kazerouni NN, Erdman DD, Lu X, Redd SC, Anderson LJ, et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol. 2007;119:314–321
  19. Baraniuk J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards LD, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest. 1999;116:625–632
  20. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844
  21. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol. 1999;82:383–389
  22. Koenig SM, Ostrom N, Pearlman D, Waitkus-Edwards K, Yancey S, Prillaman BA, et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are “stepped-down”. J Asthma. 2008;45:681–687
  23. Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, Dorinsky PM. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma. Ann Allergy Asthma Immunol. 2005;94:65–72
  24. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162:2341–2351
  25. Dolan P, Cookson R. A qualitative study of the extent to which health gain matters when choosing between groups of patients. Health Policy. 2000;51:19–30
  26. Guite HF, Dundas R, Burney PG. Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma. Thorax. 1999;54:301–307
  27. Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12:1322–1326
  28. Tough SC, Hessel PA, Ruff M, Green FH, Mitchell I, Butt JC. Features that distinguish those who die from asthma from community controls with asthma. J Asthma. 1998;35:657–665
  29. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361:1071–1076
  30. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292:367–376
  31. Wilding P, Clark M, Thompson Coon J, Lewis S, Rushton L, Bennett J, et al. Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ. 1997;314:1441–1446
  32. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60:730–734
  33. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405–1411
  34. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy. 1999;54:691–699
  35. Schleimer RP. Glucocorticoids suppress inflammation but spare innate immune responses in airway epithelium. Proc Am Thorac Soc. 2004;1:222–230
  36. Stellato C. Glucocorticoid actions on airway epithelial responses in immunity: functional outcomes and molecular targets. J Allergy Clin Immunol. 2007;120:1247–1263
  37. Stellato C, Schleimer RP. Regulation of chemokines by glucocorticoids. New York: Marcel Dekker; 2000;
  38. Carayol N, Campbell A, Vachier I, Mainprice B, Bousquet J, Godard P, et al. Modulation of cadherin and catenins expression by tumor necrosis factor-alpha and dexamethasone in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2002;26:341–347
  39. Ebnet K. Organization of multiprotein complexes at cell–cell junctions. Histochem Cell Biol. 2008;130:1–20
  40. Matter K, Aijaz S, Tsapara A, Balda MS. Mammalian tight junctions in the regulation of epithelial differentiation and proliferation. Curr Opin Cell Biol. 2005;17:453–458
  41. Coraux C, Kileztky C, Polette M, Hinnrasky J, Zahm JM, Devillier P, et al. Airway epithelial integrity is protected by a long-acting beta2-adrenergic receptor agonist. Am J Respir Cell Mol Biol. 2004;30:605–612
  42. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J. 1998;11:86–90
  43. Dowling RB, Johnson M, Cole PJ, Wilson R. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J. 1999;14:363–369
  44. Zabner J, Winter M, Excoffon KJ, Stoltz D, Ries D, Shasby S, et al. Histamine alters E-cadherin cell adhesion to increase human airway epithelial permeability. J Appl Physiol. 2003;95:394–401
  45. Winter MC, Shasby SS, Ries DR, Shasby DM. PAR2 activation interrupts E-cadherin adhesion and compromises the airway epithelial barrier: protective effect of beta-agonists. Am J Physiol Lung Cell Mol Physiol. 2006;291:L628–L635
  46. Kanthakumar K, Cundell DR, Johnson M, Wills PJ, Taylor GW, Cole PJ, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin, pyocyanin. Br J Pharmacol. 1994;112:493–498
  47. Kelly JT, Busse WW. Host immune responses to rhinovirus: mechanisms in asthma. J Allergy Clin Immunol. 2008;122:671–682
  48. Jakiela B, Brockman-Schneider R, Amineva S, Lee WM, Gern JE. Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection. Am J Respir Cell Mol Biol. 2008;38:517–523
  49. Lopez-Souza N, Dolganov G, Dubin R, Sachs LA, Sassina L, Sporer H, et al. Resistance of differentiated human airway epithelium to infection by rhinovirus. Am J Physiol Lung Cell Mol Physiol. 2004;286:L373–L381
  50. Zhu J, Rogers AV, Burke-Gaffney A, Hellewell PG, Jeffery PK. Cytokine-induced airway epithelial ICAM-1 upregulation: quantification by high-resolution scanning and transmission electron microscopy. Eur Respir J. 1999;13:1318–1328
  51. Sajjan U, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. Am J Respir Crit Care Med. 2008;178:1271–1281
  52. Bossios A, Psarras S, Gourgiotis D, Skevaki CL, Constantopoulos AG, Saxoni-Papageorgiou P, et al. Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. Respir Res. 2005;6:114
  53. Spahn J, Sheth K, Yeh WS, Stempel DA, Stanford RH. Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall. J Allergy Clin Immunol. 2009;124:1197–1203

☆ This study was funded by GlaxoSmithKline.

PII: S0954-6111(10)00058-2

doi: 10.1016/j.rmed.2010.02.007

Respiratory Medicine
Volume 104, Issue 6 , Pages 780-787 , June 2010

Article Tools

* Image Usage & Resolution